Full-Time

Head of Vaccine Medical Affairs

Vaccines

Confirmed live in the last 24 hours

Pfizer

Pfizer

10,001+ employees

Develops and manufactures biopharmaceutical products

Social Impact
Biotechnology
Healthcare

Compensation Overview

$330k - $550kAnnually

+ Bonus

Expert

No H1B Sponsorship

New City, NY, USA

Pfizer Site Location: Pearl River, NY; Relocation assistance may be available based on business needs and/or eligibility.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Data Analysis

You match the following Pfizer's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • MD or PhD degree is required; with relevant specialization in infectious diseases and/or public health. Applied research, clinical development and regulatory experience preferred.
  • Internationally recognized vaccine expert among peer groups with at least 10 years of industry experience in a senior leadership role and commensurate experience (5-10 years) in the vaccine/infectious disease field.
  • Working knowledge of vaccine development and clinical regulatory strategy required.
  • Demonstration of a wide network of peers in relevant areas of vaccines (e.g., co-authors and participation on professional societies, VTCs, technical working groups, WHO committees, etc.).
  • Proven leadership skills in managing people and projects both directly and via a matrixed or indirect team.
  • Strong interpersonal skills to quickly build rapport and credibility with Pfizer leaders and key external stakeholders.
  • Ability to partner cross culturally/regionally.
  • Effective English verbal and written communication with flexibility to be clear, consistent, compliant and appropriate for a variety of settings including scientific/technical, promotional, patient/consumer, regulatory, and media.
  • In-depth understanding of the business of vaccine/drug development including clinical trial design and data interpretation, vaccine/drug development, regulatory and promotional rules/guidance, legal and compliance, issue management and business development opportunity evaluations.
Responsibilities
  • Provide medical leadership both internally and externally to the Vaccines scientific community.
  • Accountable for the vaccine medical plans that provide the comprehensive evidence generation and data communication strategies though leading the GMATs for the end-to-end Vaccines portfolio globally, regionally and at the country level.
  • Contributes to vaccine portfolio decisions from proof-of concept to launch of the assets and beyond.
  • Accountable for medical associated content/opinion for regulatory documents pertaining to vaccines and anti-virals, as well as core member of labeling and risk-benefit committees.
  • Contributes to Vaccine Therapy Area Leadership Team objectives and goals.
  • Enhance value by representing and interfacing with internal stakeholders to develop/endorse Vaccine strategies and plans and to ensure delivery of the medical components of those plans.
  • Partner with the International and US Medical Affairs Lead(s), US, Global and International commercial Leads, Global Access and Value, and Commercial Strategy Leaders to ensure medical, commercial and access alignment on key strategies, deliverables and communication globally.
  • Serve as an externally facing expert: Represent Pfizer Vaccines externally as appropriate (e.g. to senior external clinical and academic stakeholders to build and maintain strong key opinion leader relationships; and non-medical stakeholders and investors).
  • Manage talent within the team(s), including talent and succession planning with a strong emphasis on colleague mentoring and development.
  • Manage Medical Vaccine Franchise Leads and Regional Medical VPs, assuring clear roles, responsibilities and accountabilities between global and regional colleagues.
  • Provide medical oversight of brands within Vaccines and at an above brand level, addressing key strategic decisions and critical issues, as appropriate.
  • Assure clear prioritization of evidence generation, medical and scientific work, and appropriate and flexible resourcing across global, regional and country medicine teams within the therapeutic area to assure that high priority medical work is accomplished with excellent quality and in a timely manner.
  • Attract and retain an engaged and diverse group of the highest performing professionals in the field of vaccines and anti-infectives.
  • Create an environment where colleagues understand and exhibit customer focused medical professionalism in all their functions.
  • Ensure a collaborative working environment within medical and scientific functions as well as across functions on brands to drive strategic advancement.
  • Deployment of AI and data/analytics across Vaccine medical affairs group to improve quality and efficiency of operations.
Desired Qualifications
  • Experience in managing vaccine medical brand teams is preferred.
  • Experience in vaccine policy decision making.

Pfizer is a biopharmaceutical company that focuses on creating and manufacturing healthcare products, including medicines and vaccines. The company conducts extensive research and development to discover new treatments, which are then commercialized and sold to various clients such as governments, healthcare providers, and patients. Pfizer's products include vaccines, oncology treatments, and specialized medicines, with a notable contribution to the COVID-19 pandemic through its partnership with BioNTech to develop a widely used vaccine. What sets Pfizer apart from its competitors is its strong commitment to public health, exemplified by initiatives to provide vaccines to underserved populations and a continuous effort to expand its product portfolio with new approvals. The company's goal is to improve global health by ensuring access to effective treatments and vaccines.

Company Size

10,001+

Company Stage

IPO

Total Funding

$3.8B

Headquarters

New York City, New York

Founded

1849

Simplify Jobs

Simplify's Take

What believers are saying

  • Starboard Value's $1 billion stake may drive strategic changes and increase shareholder value.
  • Pfizer's investment in fibrosis treatments expands its therapeutic areas.
  • Involvement in protein modification research diversifies Pfizer's treatment offerings.

What critics are saying

  • Slowdown in COVID-19 vaccine demand impacts Pfizer's revenue streams.
  • Activist investor Starboard Value may influence Pfizer's strategic decisions.
  • Emerging biotech companies pose a threat to Pfizer's market share in immunotherapy.

What makes Pfizer unique

  • Pfizer's partnership with BioNTech led to a highly effective COVID-19 vaccine.
  • Pfizer invests in AI disease models, enhancing predictive insights for drug development.
  • Pfizer's oncology portfolio is strengthened by investments in TCR-based immunotherapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Company News

Business Wire
Jan 16th, 2025
Normunity Closes $75 Million Series B Financing to Advance Lead Drug Program Into the Clinic and Broaden Pipeline of Novel Anti-Cancer Therapies Targeting Untapped Drug Mechanisms

Normunity, a biotechnology company creating novel anti-cancer therapies, today announced that it has closed a Series B financing for $75 million. The

TechCrunch
Oct 23rd, 2024
Promise Bio exits stealth backed by Pfizer and AstraZeneca | TechCrunch

The company has made it easier to test for different protein modifications which are critical to the treatment of autoimmune diseases.

The Wall Street Journal
Oct 7th, 2024
Exclusive | Activist Starboard Value Takes $1 Billion Stake in Pfizer

The drugmaker’s shares have slumped as demand for Covid-19 vaccines and treatments had slowed.

Benzinga
Oct 3rd, 2024
Enara Bio raises $32.5 million Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens®

New investors Pfizer Ventures and M Ventures co-led the financing, with participation from all existing investors including RA Capital, Samsara BioCapital and SV Health InvestorsEnara Bio's EDAPT® platform is

Business Wire
Jul 18th, 2024
CytoReason Secures $80M from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific to Scale Its AI Disease Models and Establish US Hub in Cambridge, Massachusetts

CytoReason, a leader in developing computational disease models for predictive insights, announced today it secured an aggregated $80 million from Our